ABOS

Acumen Pharmaceuticals, Inc.

Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001576885 Biotech & Drug Discovery

$1.98 −0.08 (−3.88%)

Oct 23 4:00 PM ET · prev $2.06

Market cap

$149.0M

Micro cap

Consensus

Buy

92% Buy or better · 12 analysts

Median target

🔒 Subscribers only

1 year

−10.4%

from $2.21 · Oct 24

30 days

−11.4%

from $2.23

52-week range

$1.55–3.37

−41% from high · low Nov 19

Avg volume 20D

638.9K

shares / day

Short interest

3.08M

≈4.3% of shares · +9.8%

Days to cover

4.8

at average volume

Insider net

-$124.6K

0 buyers · 3 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read MIXED 8 reports · 90 days

Balance 1 bearish · 0 bullish · 7 neutral oldest → newest, height = score

Avg score

·High conf. 3/8

Strongest NEUTRAL Acumen Pharmaceuticals will present three posters on its Phase 2 ALTITUDE-AD trial of sabirnetug at the CTAD…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

S Feb 27 to Mar 6 2 days of insider sells: $35.1K by 1 insider, avg $3.06
R Mar 16 Acumen Pharmaceuticals (ABOS) announced a $35.75 million private pla…
R Mar 26 Acumen Pharmaceuticals reported its 2025 financial results, showing…
S Jun 9 to Jun 17 4 days of insider sells: $89.5K by 2 insiders, avg $2.31
E Oct 22 FDA: Acumen Pharmaceuticals to Present Preliminary Baseline Cha…

Signal stack

Where each data set points today.

InsidersBEARISH

3 insiders sold $124.6K.
InstitutionsBULLISH

Q2 2026: 15 added (0 new), 8 trimmed or exited.
AnalystsBULLISH

11 of 12 rate it Buy or better.
Short sellersSTEADY

Short interest +9.8% to 3.08M shares. 4.8 days to cover, ≈4.3% of shares.
TrendDOWNTREND

21% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
BlackRock, Inc.	DOUBLED	2,490,115	$6.6M
GEODE CAPITAL MANAGEMENT, LLC	DOUBLED	1,141,858	$3.0M
RENAISSANCE TECHNOLOGIES LLC	ADD	675,025	$1.8M
STATE STREET CORP	DOUBLED	600,528	$1.6M
NORTHERN TRUST CORP	DOUBLED	360,744	$963.2K
DIMENSIONAL FUND ADVISORS LP	DOUBLED	291,559	$779.0K
VANGUARD FIDUCIARY TRUST CO	ADD	291,240	$777.6K
SUSQUEHANNA INTERNATIONAL GROUP, LLP	NEAR_EXIT	126,104	$336.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts

Buy 92% rate it Buy or better

Strong Buy6Buy5Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access

Recent actions

Date	Firm	Action	Rating
Sep 16, 2026	BTIG REITERATE	REITERATE	Buy
Sep 15, 2026	Citigroup MAINTAIN	MAINTAIN	Buy

Insider ledger

Form 4

bought · 0 insiders

$124.6K

sold · 3 insiders

Date	Insider	Type	Value
Jun 17, 2026	Porter Derrell Director	EXERCISE	$14.0K
Jun 17, 2026	Porter Derrell Director	SELL	$30.3K
Jun 16, 2026	Porter Derrell Director	SELL	$29.8K
Jun 15, 2026	Porter Derrell Director	EXERCISE	$6.9K
Jun 15, 2026	Porter Derrell Director	SELL	$15.1K
Jun 9, 2026	Fountain Nathan B Director	SELL	$14.3K
Jun 3, 2026	Stoppel Laura Director	AWARD	53,250 sh
Jun 3, 2026	Ives Jeffrey L. Director	AWARD	53,250 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

Period	EPS est.	Range	30D rev.	Revenue
Current Q	🔒 Fresh data — subscribers only
Next Q	🔒 Fresh data — subscribers only
Current FY	🔒 Fresh data — subscribers only
Next FY	🔒 Fresh data — subscribers only